Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008
Most Surveyed MCO Pharmacy Directors Will Move Razadyne and Razadyne ER
from Tier 2 to Tier 3 When Generic Razadyne is Launched, According to a New Report from Decision Resources
WALTHAM, Mass., July 9 /PRNewswire/ -- Decision Resources, one of the
world's leading research ...
Drug May Stem Slide Into Alzheimer's for Some
did not help others with mild memory loss, study finds,,
MONDAY, June 15 (HealthDay News) -- Depression might increase the chance of devel...
Death on the Net? Over 60% of Medicines Sold by Online Pharmacies are Fake
...inger- Ingelheim), Spiriva (Boehringer-Ingelheim) Mental Health: Zyprexa (Lilly), Efexor (Wyeth), Risperdal (J&J) Alzheimer's disease: aricept
(Pfizer), Reminyl (Shire) Men's health: Cialis (Lilly), Levitra (Bayer-Schering), Viagra (Pfizer), Propecia (MSD) Other: Zoton (Wyeth)...
A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimer's Disease Drug Market
...es, physicians believe that, if such a
therapy were launched, it would threaten a significant percentage of
prescriptions of donepezil (Eisai/Pfizer's aricept
and Bracco's Memac) and
the memantine/donepezil combination.
The report also finds that a therapy's effect on cognitive decline is
the attribute tha...
New Stroke Therapies Show Promise
... which sucks clots out of the brain, was effective for eight hours after the onset of a stroke, adding five hours to a patient's treatment window.
(donepezil) improved several measures of executive function and processing speed in patients with a subcortical form of vascular dementia but did not ...
Memantine and Alzheimer's disease
...to the death of neurones.
The first-generation of compounds aimed to boost the brains acetylcholine levels led to the development of drugs such as aricept
(donepezil) and Excelon (rivastigmine). Attempts to develop drugs that block the action of glutamate by a considerable number of pharmaceutical compan...
Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less
... placebo, only 10 to 20 percent of people taking any of the
drugs had sustained improvement. Despite these results, two of the five
Alzheimer's drugs, aricept
and Namenda, were among the top 100 best-selling
brand-name drugs in 2006. Promotions of both drugs to doctors have been
extensive. Aricept's maker sp...
Alzheimer's Drug Won't Ease Patients' Agitation
... But aricept
may help stave off cognitive decline, researchers ...rase inhibitors -- the class of medicines to which aricept
(donepezil) belongs -- in easing agitation. Howeve...s can be severe.
Cholinesterase inhibitors like aricept
have been shown to improve cognitive outcomes but ...
Drugs Watchdog Faces A Judicial Review
...at sufferers with early or late-stage Alzheimer's should not have access to aricept
(donepezil), Reminyl galantamine) or Exelon (rivastigmine). Ebixa (memantin...to severe conditions of Alzheimer's disease.
Judicial review regarding aricept
has been granted to Eisai, the licence holder of Aricept, and Pfizer, its c...
Aricept Cleared for Advanced Alzheimer's Treatment
becomes the first drug to be cleared for treatment of all stages of Alzheim...nt's death after much mental deterioration. Doctors are already prescribing aricept
for the advanced stages, so the approval only gives an official status to t...
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Physician Familiarity and its Better Side-Effect/Safety Profile are Driving Aricept
Prescription Rates, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory fir...
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
TOKYO and WOODCLIFF LAKE, N.J., Dec. 27 /PRNewswire/ --- Eisai Co.,
Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc.
(Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) (collectively
"Eisai") filed a lawsuit in August 2006 against Mutual Pharmaceutical Co.,
Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept
Following its Launch in 2010, Myriad Genetics' Flurizan Will Earn a 23%
Patient Share in the United States, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 5 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisor...
Alzheimer's drug market to hit $5.5 billion by 2009, study says
... against Alzheimer's. The technology is patented by the Wisconsin Alumni Research Foundation .
The Millennium report forecasts that Eisai/Pfizer's aricept
will continue to dominate the Alzheimer's drug market and predicts strong growth of memantine-based drugs such as Forest Laboratories' Namenda. While ...